Abstract
Endotoxin or lipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria. Like aeroallergens, LPS is ubiquitous in our living environment. Epidemiology studies in young children have found that LPS exposure at home is inversely correlated with the development of atopic diseases, thus the 'hygiene hypothesis' for allergic diseases. However, positive association has also been found between indoor LPS exposure and the development of wheezing or asthma in children. In humans, experimental exposure to LPS in the airways can cause inflammatory responses and lung function changes directly or modulate responses to allergens indirectly, particularly in those with asthma. In animal studies, experimental exposure to LPS has generated some conflicting, sometimes opposite, results in host responses to allergen stimulation. In this article, we will review recent advances in our understanding of the immunomodulating effects of LPS on allergen-induced responses and analyse some of the possible reasons for the inconsistent findings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 536-546 |
| Number of pages | 11 |
| Journal | Clinical and Experimental Allergy |
| Volume | 40 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2010 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Immunomodulating effects of endotoxin in mouse models of allergic asthma. / Zhu, Z.; Oh, S. Y.; Zheng, T.; Kim, Y. K.
In: Clinical and Experimental Allergy, Vol. 40, No. 4, 04.2010, p. 536-546.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunomodulating effects of endotoxin in mouse models of allergic asthma
AU - Zhu, Z.
AU - Oh, S. Y.
AU - Zheng, T.
AU - Kim, Y. K.
PY - 2010/4
Y1 - 2010/4
N2 - Endotoxin or lipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria. Like aeroallergens, LPS is ubiquitous in our living environment. Epidemiology studies in young children have found that LPS exposure at home is inversely correlated with the development of atopic diseases, thus the 'hygiene hypothesis' for allergic diseases. However, positive association has also been found between indoor LPS exposure and the development of wheezing or asthma in children. In humans, experimental exposure to LPS in the airways can cause inflammatory responses and lung function changes directly or modulate responses to allergens indirectly, particularly in those with asthma. In animal studies, experimental exposure to LPS has generated some conflicting, sometimes opposite, results in host responses to allergen stimulation. In this article, we will review recent advances in our understanding of the immunomodulating effects of LPS on allergen-induced responses and analyse some of the possible reasons for the inconsistent findings.
AB - Endotoxin or lipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria. Like aeroallergens, LPS is ubiquitous in our living environment. Epidemiology studies in young children have found that LPS exposure at home is inversely correlated with the development of atopic diseases, thus the 'hygiene hypothesis' for allergic diseases. However, positive association has also been found between indoor LPS exposure and the development of wheezing or asthma in children. In humans, experimental exposure to LPS in the airways can cause inflammatory responses and lung function changes directly or modulate responses to allergens indirectly, particularly in those with asthma. In animal studies, experimental exposure to LPS has generated some conflicting, sometimes opposite, results in host responses to allergen stimulation. In this article, we will review recent advances in our understanding of the immunomodulating effects of LPS on allergen-induced responses and analyse some of the possible reasons for the inconsistent findings.
UR - http://www.scopus.com/inward/record.url?scp=77949415690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949415690&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2222.2010.03477.x
DO - 10.1111/j.1365-2222.2010.03477.x
M3 - Article
VL - 40
SP - 536
EP - 546
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
SN - 0954-7894
IS - 4
ER -